Small Intestinal Fungal Overgrowth

  title={Small Intestinal Fungal Overgrowth},
  author={Aşkın Erdoğan and Satish S. C. Rao},
  journal={Current Gastroenterology Reports},
Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms in the small intestine associated with gastrointestinal (GI) symptoms. Candidiasis is known to cause GI symptoms particularly in immunocompromised patients or those receiving steroids or antibiotics. However, only recently, there is emerging literature that an overgrowth of fungus in the small intestine of non-immunocompromised subjects may cause unexplained GI symptoms. Two recent… 
Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management
The SIBO landscape is poised for transformation through improved awareness and scientific rigor, and limited numbers of controlled studies have shown systemic antibiotics to be efficacious.
Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)?
Patients with colectomy demonstrate significantly higher prevalence of SIBO/SIFO and greater severity of gastrointestinal symptoms and response to treatment.
Gastroduodenal “Dysbiosis”: a New Clinical Entity
Alterations of the SI-MAM appear to play a key role for the manifestation and progression of inflammatory and metabolic disorders.
Clinical Conditions Associated With Bacterial Overgrowth
The duodenal microbiome is altered in small intestinal bacterial overgrowth
The results validate the >103 CFU/mL cutoff for the definition of SIBO, and also reveal specific overgrowth of Proteobacteria in SIBO vs. non-SIBO subjects, coupled with an altered proteobacterial profile that correlates with symptom severity.
Current and Future Approaches for Diagnosing Small Intestinal Dysbiosis in Patients With Symptoms of Functional Dyspepsia
There is emerging data that targeted antimicrobial treatment of SIBO in patients with FD who simultaneously may or may not have IBS, results in symptom improvement and normalization of positive breath tests, however, the association between SIBO and FGIDs remains controversial, since widely accepted diagnostic tests for SIBO are lacking.
Small-bowel aspiration during upper esophagogastroduodenoscopy: Rao technique
ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.
This guideline statement evaluates criteria for diagnosis, defines the optimal methods for diagnostic testing, and summarizes treatment options for small intestinal bacterial overgrowth.
Diagnosis and treatment of mucosa Candida spp . infections – a review
Results of many studies indicate that there is no need to implement treatment in sexual partners of patients suffering from VVC / rVVC, and more effective oral terbinaine or itraconazole is used instead of oral griseofulvin.


Fungal infections of the small and large intestine.
Variable gross appearances of fungal infections affecting the lower intestinal tract are relevant for endoscopists, particularly lesions which resemble pseudomembranous colitis, and endoscopic biopsy specimens may have a role in antemortem diagnosis.
An Unusual Case Report of Small Bowel Candida Overgrowth as a Cause of Diarrhea and Review of the Literature
This report is a rare case of an immunocompetent individual with noninvasive small-bowel candidiasis presenting with diarrhea.
Host defense mechanisms in invasive candidiasis originating in the GI tract
Results on a new murine model of systemic candidiasis originating in the GI tract that might prove a valuable setting for the accurate study of host immune mechanisms, fungal virulence factors and novel therapeutic approaches are evaluated.
Yeasts in the gut: from commensals to infectious agents.
The eradication of intestinal yeasts is advised only for certain clearly defined indications.
Fungal flora of the normal human small and large intestine.
The stability of the mycofloral pattern of the small intestine was demonstrated in five subjects who were resampled five to nine months after the initial studies; the fungal pattern was qualitatively and quantitatively unchanged.
Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts.
  • M. Ruhnke
  • Medicine, Biology
    Current drug targets
  • 2006
The current epidemiological trends in mucosal and invasive candidiasis are discussed with regard to the role of non-Candida albicans species as the causative agent in immunocompromised patients.
Management of invasive fungal infections: a role for polyenes.
  • P. Chandrasekar
  • Medicine, Biology
    The Journal of antimicrobial chemotherapy
  • 2011
The oldest antifungal drugs, polyenes, remain useful in the treatment of IFIs because of their broad-spectrum activity, low rates of resistance and established clinical record, particularly in immunocompromised patients with breakthrough fungal infections.
Echinocandin antifungal drugs